Freshly harvested intratumoral and nontumoral liver tissues, obtained by needle liver biopsy, were transferred to Hypothermosol™ FRS solution, and cells were recovered through mechanical disruption. Samples of whole fresh peripheral blood (100 µL/tube) and intrahepatic cell suspensions were divided into two tubes and immunostained with the following anti-human antibodies for surface markers: anti-CD45-APC/Cy7 (clone HI30, BioLegend), anti-CD3-PerCP-Cy5.5 (clone UCHT1, BioLegend), anti-CD56-BV605 (clone HCD56, BioLegend), anti-CD16-AF700 (clone 3G8, BioLegend), anti-CD8-PE/Cy7 (clone RPA-T8, BD Biosciences), anti-CD69-PE (clone FN50, BioLegend), anti-CTLA4-BV421 (clone BNI3, BioLegend), anti-PD-1-BV711 (clone EH12.2H7, BioLegend), anti-LAG3-PE (clone 3DS223H, eBioscience), anti-OX40-FITC (clone Ber-ACT35, BioLegend), anti-4-1BB-BV421 (clone 4B4-1, BioLegend), and anti-TIM3-BV785 (clone F39-2E2, BioLegend). FluoroFix™ Buffer (BioLegend) was used to fix the cells. The Zombie UV™ Fixable Viability kit was used to exclude dead cells, and fluorescence minus one controls were used to determine the positive immune cell population. Data were acquired with the BD-LSRII flow cytometer (BD Biosciences), collected using BD FACSDiva 6.3.1 software and analyzed using FCS Express 7 Flow software, using the previously described gating strategy,24 (link)
Figure S1.